Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy-Reference-Cited by-同舟云学术

Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy

Published:2024-04-09 Issue:3 Volume:32 Page:267-280
ISSN:1976-9148
Container-title:Biomolecules & Therapeutics
language:en
Short-container-title:Biomol Ther (Seoul)

Author:

Dakkak Bisan El¹,Taneera Jalal¹²,El-Huneidi Waseem¹²,Abu-Gharbieh Eman¹²,Hamoudi Rifat¹²³,Semreen Mohammad H.¹⁴,Soares Nelson C.¹⁴⁵,Abu-Rish Eman Y.⁶,Alkawareek Mahmoud Y.⁶,Alkilany Alaaldin M.⁷,Bustanji Yasser¹²⁶

Affiliation:

1. Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates

2. College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates

3. Division of Surgery and Interventional Science, University College London, London, United Kingdom

4. College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates

5. Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon 1649-016, Portugal

6. School of Pharmacy, The University of Jordan, Amman 11942, Jordan

7. College of Pharmacy, QU Health, Qatar University, Doha 2713, Qatar

Funder

University of Sharjah

University of Jordan

Publisher

The Korean Society of Applied Pharmacology

Link

https://pdf.medrang.co.kr/BT2/2024/032/BT032-03-01.pdf

Reference119 articles.

1. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumoursin vivo

2. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

3. Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

4. Synthesis and in vitro behavior of iron-crosslinked N-methyl and N-benzyl hydroxamated derivatives of alginic acid as controlled release carriers

5. Encapsulation of echinomycin in cyclodextrin inclusion complexes into liposomes: in vitro anti-proliferative and anti-invasive activity in glioblastoma